Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deucravacitinib

FDA-approved product (tablet, oral), marketed as Sotyktu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Deucravacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Tyrosine Kinase 2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deucravacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deucravacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Taste Assessment of BMS-986165 in Healthy Participants

    NCT03751228 · start 2018-10-11

    Registered record
    Registry ID
    NCT03751228
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; Active Pharmaceutical Ingredient
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-11
    Completion
    2018-11-26
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; Active Pharmaceutical Ingredient
    PhasePhase 1
    Registry statusCompleted

  • Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

    NCT03624127 · start 2018-08-07

    Registered record
    Registry ID
    NCT03624127
    Conditions
    Psoriasis
    Interventions
    BMS-986165; Placebo; Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-07
    Completion
    2020-09-02
    Enrolment
    666

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionBMS-986165; Placebo; Apremilast
    PhasePhase 3
    Registry statusCompleted

  • A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

    NCT03402087 · start 2018-01-08

    Registered record
    Registry ID
    NCT03402087
    Conditions
    Lupus; Psoriatic Arthritis
    Interventions
    Methotrexate; Leucovorin; BMS-986165
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-08
    Completion
    2018-03-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus; Psoriatic Arthritis
    InterventionMethotrexate; Leucovorin; BMS-986165
    PhasePhase 1
    Registry statusCompleted

  • The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

    NCT03262727 · start 2017-09-01

    Registered record
    Registry ID
    NCT03262727
    Conditions
    Systemic Lupus Erythematosus; Arthritic Psoriasis; Psoriasis; Inflammatory Bowel Diseases
    Interventions
    BMS-986165; Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2017-12-19
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus; Arthritic Psoriasis; Psoriasis; Inflammatory Bowel Diseases
    InterventionBMS-986165; Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
    PhasePhase 1
    Registry statusCompleted

  • PsoBest - The German Psoriasis Registry

    NCT01848028 · start 2008-01

    Registered record
    Registry ID
    NCT01848028
    Conditions
    Psoriasis; Psoriatic-arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-01
    Completion
    2032-12
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Psoriatic-arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting